Our Journey

Why Coriolis
Our Journey
The Coriolis Effect Our Facilities Meet the Team Careers

Coriolis Pharma has grown from a pioneering academic spinout to a leading force in the biologics industry. Our journey is marked by innovation, expansion and a relentless commitment to advancing biologics development. Explore how our milestones reflect our growth and position us as a critical player in the dynamic world of biologics and gene and cell therapies.

Milestones

2024: Establishment of U.S. Business Entity

Expanded global footprint by establishing a U.S. business entity, enhancing our ability to serve clients in North America. This strategic move also supported the launch of our innovative Accelerator Programs, designed to fast-track drug product development from early-stage research to phase I clinical trial readiness.

2023: 15th Anniversary and Strategic Investment by KKR

Celebrating 15 years of excellence, we welcomed a strategic investment from KKR to fuel our next growth phase. This partnership underscores our commitment to expanding our capabilities and driving the development of biologics.

2022: Expansion for ATMP Development

In response to the emerging advanced therapy medicinal products (ATMPs) field, we expanded into new facilities equipped to handle up to biosafety level 2. This investment positioned us at the forefront of ATMP development, supporting gene and cell therapy innovations.

2017: New Facilities in Martinsried

Our move to larger facilities in Martinsried enabled us to increase our operational capacity and offer more advanced services. The growing demand for our formulation and analytical services expertise drove this expansion.

2017: Biosafety Level (BSL) 1 & 2 Certification

With the addition of BSL 1 and 2 certifications, we enhanced our capabilities to handle a broader range of biologics, including advanced therapies. This expansion was crucial in meeting the evolving needs of the market and our clients.

2012: GMP Accreditation

Achieving good manufacturing practice (GMP) accreditation marked a significant milestone. It allowed us to expand our services to include comprehensive analytical and non-GMP manufacturing support, solidifying our reputation for quality and compliance.

2009: Expansion to the IZB in Martinsried

We moved to the Innovations- und Gründerzentrum Biotechnologie (IZB) in Martinsried near Munich to support our growing team and capabilities, fostering a collaborative environment that enhanced our research and development efforts.

2008: Foundation of Coriolis Pharma

Coriolis Pharma was established with a vision to transform biologics formulation. Our roots in academic excellence provided a solid foundation for our early focus on innovative formulation services for biologics.

Navigating the Biologics Landscape

Throughout our history, Coriolis Pharma has adapted to the rapidly changing biologics market, consistently staying ahead of industry trends and technological advancements. From our early days of pioneering formulation services to our current role as a comprehensive partner in biologics development, we have continually evolved to meet the needs of our clients.

Our expertise in early-stage formulation, robust analytical support and advanced manufacturing solutions enable us to tackle complex challenges and accelerate drug development. As we look to the future, we remain dedicated to leveraging our scientific prowess and innovative spirit to lead biologics and ATMP development.

Explore More with Coriolis

Talk to Our Experts or Request a Quote

Our expert team is ready to answer your questions and guide you to the services best suited to your program’s modality, stage and challenge. If your needs are well-defined, we’ll begin the quotation process.

Description